stockrow
Friday 6 November 2026
Export DARE’s income statement to Excel — free account
Dare Bioscience, Inc.
DARE Healthcare Biotechnology
Dare Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, up 10,412.2% from fiscal 2024.
- Revenue
- +984.4%
- EPS
- +55.6%
- Free cash flow
- −30.2%
Quarter to June 2026, against a year earlier
0.64
0.02
+3.23%
Follow DARE
Alert me
Dare Bioscience, Inc. (DARE) P/E ratio
Dare Bioscience, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 2.1× (March 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.1×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AEON AEON Biopharma, Inc. compare | n/m |
| HIND Vyome Holdings, Inc. compare | n/m |
| GUTS Fractyl Health, Inc. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| BOLT Bolt Biotherapeutics, Inc. compare | n/m |
| DARE Dare Bioscience, Inc. | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)